News and Trends 13 Dec 2016 How Will Biotech Overcome the Huge Challenges of Microbial Resistance? The emergence of multi-drug resistant pathogens is alarming the scientific community since their growth is increasing at an incredibly fast pace. We gathered a group of experts to discuss how biotech is addressing this pressing concern and what the next big thing will be in the field of antimicrobial resistance. Achim Plum, CCO of Curetis, highlighted that […] December 13, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2016 European Pharma closes 2016 by launching new Biotech Startups Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016 by investing in a pair of new ventures. Bayer and Versant have invested $225M to launch BlueRock Therapeutics, which will focus on CNS and cardiovascular diseases. This comes […] December 13, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 French Biotech Puts a New Lyme Disease Vaccine on the Horizon There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […] December 12, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 Meet Photanol: Harnessing Cyanobacteria’s Powers for Green Chemicals Producing fuels and chemicals from CO2 and light has long been a dream of Biotech, and Amsterdam-based Photanol is working on making it an industrial reality with engineered cyanobacteria. I had a chat with Ross Gordon, Director of Business Development, about Photanol’s strategy. Photanol was present at the latest European Bioplastics Conference to present how it uses cyanobacteria, […] December 12, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 A New Antibiotic from Your Nose! Thanks to Functional Genomics Could your nose lead to major discoveries in antibiotic production? Genome mining of nose bacteria has revealed a new powerful antibiotic. Functional genomics offers a powerful tool for the isolation and detection of novel antibiotics, as the data obtained from it can be used to describe gene functions and interactions. The human microbiome has been largely […] December 12, 2016 - 2 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2016 With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success. December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number […] December 12, 2016 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Paris takes the lead in Digital Health for Diabetes Type 2 The smell of freshly baked baguettes and good news from the capital have brought us this week to France. Voluntis has received market approval for a device that could change the life of millions of people with diabetes type 2, check out this cool company! City: Paris, France Founded: 2001 Employees: 100 Financial data: Total of €29.8M raised in […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Galapagos gets another Milestone Payment from Gilead Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […] December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Our Startup Battle Winner uses CRISPR in a Whole New Way Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […] December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Lifting the Chemo Fog: Virtual Reality has Medical Applications! Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […] December 9, 2016 - 3 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email